Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus

U Lorenz, K Ohlsen, H Karch, M Hecker… - FEMS Immunology & …, 2000 - academic.oup.com
U Lorenz, K Ohlsen, H Karch, M Hecker, A Thiede, J Hacker
FEMS Immunology & Medical Microbiology, 2000academic.oup.com
The identification of target structures is a prerequisite for the development of new treatment
options, like antibody based therapy, against methicillin resistant Staphylococcus aureus
(MRSA). In this study we identified immunodominant structures which were expressed in
vivo during sepsis caused by MRSA. Using human sera we compared the immune response
of humans with MRSA sepsis with the immune response of normal individuals and
asymptomatically colonized individuals. We identified and characterized four staphylococcal …
Abstract
The identification of target structures is a prerequisite for the development of new treatment options, like antibody based therapy, against methicillin resistant Staphylococcus aureus (MRSA). In this study we identified immunodominant structures which were expressed in vivo during sepsis caused by MRSA. Using human sera we compared the immune response of humans with MRSA sepsis with the immune response of normal individuals and asymptomatically colonized individuals. We identified and characterized four staphylococcal specific antigenic structures. One target is a staphylococcal protein of 29 kDa that exhibited 29% identity to secreted protein SceA precursor of Staphylococcus carnosus. The putative function of this protein, which was designated IsaA (immunodominant staphylococcal antigen), is unknown. The second target is an immunodominant protein of 17 kDa that showed no homology to any currently known protein. This immunodominant protein was designated IsaB. The third and fourth antigens are both immunodominant proteins of 10 kDa. One of these proteins showed 100% identity to major cold shock protein CspA of S. aureus and the other protein was identified as the phosphocarrier protein Hpr of S. aureus. The identified immunodominant proteins may serve as potential targets for the development of antibody based therapy against MRSA.
Oxford University Press